<DOC>
	<DOCNO>NCT02497716</DOCNO>
	<brief_summary>To characterize pharmacokinetic profile rivaroxaban administer granule suspension formulation document safety tolerability</brief_summary>
	<brief_title>Phase I Study Rivaroxaban Granules Oral Suspension Formulation Children</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Children age â‰¥2 month weight 3 &lt; 12 kg , complete anticoagulant treatment least 10 day prior plan study drug administration . Gestational age birth least 37 week Oral feeding/ nasogastric/ gastric feed least 10 day Normal PT aPTT within 10 day prior plan study drug administration Written inform consent provide , applicable , child assent provide Active bleed high risk bleeding , contraindicate anticoagulant therapy Planned invasive procedure , include removal central line , within 24 hour single dose intake An estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73m2 Hepatic disease associate either : coagulopathy lead clinically relevant bleeding risk , alanine aminotransferase ( ALT ) &gt; 5x upper level normal ( ULN ) , total bilirubin &gt; 2x ULN direct bilirubin &gt; 20 % total . Platelet count &lt; 50 x 10^9/L Hypertension ( define systolic and/or diastolic blood pressure &gt; 95th percentile age ) Concomitant use strong inhibitor CYP3A4 Pglycoprotein , e.g. , human immunodeficiency virus protease inhibitor follow azoleantimycotic agent : ketoconazole , itraconazole , voriconazole , posaconazole , use systemically ( fluconazole allow ) Concomitant use strong inducer CYP3A4 , e.g. , rifampicin , rifabutin , phenobarbital , phenytoin carbamazepine Inability cooperate study procedure Hypersensitivity rivaroxaban Participation study investigational drug rivaroxaban medical device within 30 day prior treatment History gastrointestinal disease surgery associate impaired absorption</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>